Instruction 1(b).

FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1   |  | Name and Address of Reporting Person*     Sweeny Nicole |   |         |   |                 |  | 2. Issuer Name and Ticker or Trading Symbol Praxis Precision Medicines, Inc. [ PRAX ] |  |        |              |   |                       |                          |   | licable)<br>tor<br>er (give title  | ng Person(s) to I<br>10% C<br>Other |  |  |
|---|--|---|---|---------|---|-----------------|--|---|--|--------|--------------|---|-----------------------|--------------------------|---|--|-------------------------------------|--|--|
| (Last) (First) (Middle) C/O PRAXIS PRECISION MEDICINES, INC. 99 HIGH STREET, 30TH FLOOR |  |   |   |         | 3. Date of Earliest Transaction (Month/Day/Year) 02/12/2022 |                 |  |   |  |        |              |   | X                     | belov                    |   |  | below)                              |  |  |
| (Street) BOSTON MA 02110 (City) (State) (Zip)   |  |   |   | 4. If A | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |                 |  |   |  |        |              |   | 6. Indi<br>Line)<br>X | ·                        |   |  |                                     |  |  |
|   | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   |   |   |         |   |                 |  |   |  |        |              |   |                       |                          |   |  |                                     |  |  |
| 1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)                          |  |   |   |         |   | Execution Date, |  |   |  |        |              | es Acquired (A)<br>Of (D) (Instr. 3, 4  |                       | 4 and Securit<br>Benefic |   | ties<br>cially<br>Following  | Forn<br>(D) o                       | wnership<br>n: Direct<br>or Indirect<br>nstr. 4)                         | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)  |
|   |  |   |   |         |   |                 |  | Code  | v  | Amount | (A) (<br>(D) | Pri   | се                    | Transa                   | action(s)<br>3 and 4)                     |  |                                     | (  |  |
| Common Stock 02/12/20   |  |   |   |         | .022  |                 |  |   | F <sup>(1)</sup>                                   |        | 1,233        | D \$1   |                       | 12.85                    | 39,567                                    |  |                                     | D  |  |
|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |   |   |         |   |                 |  |   |  |        |              |   |                       |                          |   |  |                                     |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                                     | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | 3. Transaction<br>Date<br>(Month/Day/Year)              | Execution Date, if any (Month/Day/Year) |         | 4.<br>Transaction<br>Code (Instr. 8)                        |                 | of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |   | 6. Date Exercisal Expiration Date (Month/Day/Year) |        | te<br>ear)   | 7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)  Amou or Numb of Title Share: |                       | De Se (In:               | Price of<br>rivative<br>curity<br>str. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) |                                     | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |

## **Explanation of Responses:**

1. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported Restricted Share Units.

## Remarks:

/s/ Alex Nemiroff, as Attorney-in-Fact

02/15/2022

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.